A new study provides evidence that blood epigenetic biomarkers contain “snapshots” of past cardiovascular health exposures and behavior at the molecular level.
Menu
Browsing: Cancer
Proteins gain new interactions that are potentially oncogenic and could drive cancer development and growth, according to a recent study.
Patients with advanced kidney cancer who received a new combination treatment reported improved health-related quality of life outcomes, according to a Northwestern Medicine study.
Calcium channel blockers may improve treatment for patients with pancreatic cancer receiving chemotherapy, according to a recent study.
A deep learning model has discovered genetic variations in cancer that are undetectable in traditional genome sequencing.
Jody Ciolino, PhD, and Masha Kocherginsky, PhD, faculty in the Department of Preventive Medicine Division of Biostatistics, were elected to the Board of Directors for the Society for Clinical Trials (SCT).
A newly discovered inhibitor of a common cancer-causing protein operates selectively, reducing expression of genes that fuel rampant cell proliferation, and altering the epigenome, according to a recent study.
A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies.
The Cancer Immunology and Immunotherapy Initiative at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University is bringing together Feinberg investigators who study immunotherapy to increase collaboration and accelerate high-impact immunotherapy research.
Investigators have discovered the mechanisms underlying a T-cell receptor’s immunosuppressive function, findings that may improve the development of precision therapeutics for chronic disease, including cancer.